After nearly a decade of working as an advocate for HIV and AIDS treatment, Michael Chancley said he came to a sobering realization. “Seeing that people who look like me, who hang out at the same ...

HIV/AIDS activists heralded the approval of a new twice-yearly pre-exposure prophylaxis (PrEP) medication last year, but ...

ATLANTA — Five years ago, the U.S. government unveiled a plan to end the HIV epidemic by 2030. More than 30,000 people are diagnosed with HIV every year in this country. But this is not a problem for ...

In this interview, Emma Kaplan-Lewis, M.D., clinical quality director for HIV, hepatitis and sexual health services at NYC ...

When it comes to HIV prevention, few tools have been as game-changing as PrEP — short for pre-exposure prophylaxis. Yet, despite its effectiveness, many people still aren’t sure whether it’s right for ...

Novel findings attend to attitudes of the stigmatized, rather than stigmatizers Past research identified perception of promiscuity and assumptions that PrEP users are HIV-positive as key drivers of ...

In observance of HIV/AIDS Awareness Month and to further the Shapiro Administration's commitment to Pennsylvanians' wellbeing, the Pennsylvania Insurance Department (PID) and the Department of Health ...

In June, Gilead Sciences announced impressive early results from its PURPOSE 1 trial, which showed 100 percent efficacy of lenacapavir in preventing new HIV infections among cisgender women in ...

According to preliminary data released by the CDC in October, there was an increase in PrEP prescriptions from 2019 to 2022, but "severe and widening inequities persist." The CDC also noted that ...